NC State Study Establishes First Canine MHC Class II Binding Motifs

In the immune response, specialized cells process proteins into small fragments displayed on their surfaces by MHC class II proteins, which play a critical role in identifying threats. While much is known about these processes in humans and mice, similar mapping for dogs has been lacking until now.

Dr. Haeree Lang, a postdoctoral fellow at NC State’s College of Veterinary Medicine, has published a study in The Journal of Immunology outlining the first allele-specific framework that describes how canine MHC class II molecules bind to peptides. This framework identifies the binding motifs for two common canine MHC class II alleles: DLA-DR15, prevalent in Standard Poodles, and DLA-DR12, commonly found in Golden Retrievers. These breeds often exhibit predispositions to immune-mediated diseases, autoimmune disorders, and cancer.

Lang indicated the challenge faced by the field of canine immunology, noting that many existing studies rely on outdated methods while human and mouse research has progressed significantly through advanced technologies like single-cell RNA sequencing.

The research team focused on the Dog Leukocyte Antigen (DLA) region, where MHC class II genes reside. They developed engineered cell lines expressing only one of the two molecules, allowing accurate analysis. Their subsequent use of mass spectrometry on peptides from canine spleen tissue led to the identification of distinct binding motifs for each allele.

To validate their framework, the researchers utilized the rabies vaccine, which is mandated for dogs in the U.S. The team predicted binding peptides for the DLA-DR15 and DLA-DR12 alleles, successfully confirming several with binding assays.

Notably, the canine DLA-DR motifs were found to closely resemble human HLA-DR, more so than in lab mice, suggesting dogs may serve as a more relevant model for exploring human immunological processes due to their shared environments and diseases.

This research could lead to enhanced tools for canine immunologists, creating better-vetted vaccines, improved cancer immunotherapy targeting, and insights into why certain breeds are more vulnerable to autoimmunity. Lang aspires to expand the study to other DLA alleles and assess T cell responses directly, ultimately aiming to characterize antigen-specific responses in canine patients.

The overarching goal is to position dogs as key comparative models for studying human immunology, capitalizing on their close relationship with humans and offering new avenues for vaccine and therapy development. The study provides a crucial, contemporary framework that may lead to superior diagnostics and treatments for immune-mediated diseases, benefiting both canine and human health.